Treatment of Anemia in Chronic Kidney Disease
Initial Evaluation and Iron Repletion
- The National Kidney Foundation recommends treating CKD-related anemia with iron supplementation first, followed by erythropoiesis-stimulating agents (ESAs) if needed, targeting hemoglobin 10-12 g/dL, to reduce transfusion needs while minimizing cardiovascular risks and mortality 1, 2, 3, 4
- Before initiating any anemia treatment, perform baseline tests, including complete blood count, absolute reticulocyte count, serum ferritin level, transferrin saturation (TSAT), and serum vitamin B12 and folate levels 1, 2
- Iron supplementation is the first-line intervention when TSAT ≤30% and ferritin ≤500 ng/mL in patients not yet on ESA therapy, with either intravenous iron or a 1-3 month trial of oral iron appropriate for non-dialysis CKD patients 1, 2, 3
- Monitor iron status (TSAT and ferritin) at least every 3 months during treatment 3
ESA Therapy Initiation
- Initiate ESA therapy when iron stores have been corrected, other reversible causes of anemia have been treated, and hemoglobin remains below 10 g/dL despite iron repletion 1, 2, 4, 5
- The American Society of Nephrology recommends targeting hemoglobin levels between 10-12 g/dL, as higher levels may increase cardiovascular risks 1, 2, 3, 4, 5
- Critical contraindications and cautions for ESA use include active malignancy, history of stroke, and uncontrolled hypertension 1, 2
ESA Hyporesponsiveness
- Classify patients as ESA-hyporesponsive if hemoglobin does not increase from baseline after the first month of appropriate weight-based ESA dosing 2
- Investigate causes of ESA hyporesponsiveness, including absolute or functional iron deficiency, infection or inflammation, hyperparathyroidism, aluminum toxicity, folate or vitamin B12 deficiency, blood loss, hemolysis, bone marrow disorders, malignancy, and malnutrition 2, 8, 9, 10